Summary
230.62 0.58(0.25%)05/17/2024
Biogen Inc (BIIB)
Biogen Inc (BIIB)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.15 | 1.89 | 6.80 | -9.00 | -10.88 | -30.38 | -4.43 | 6,904.16 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 218.88 | |
| Open | 221.52 | |
| High | 221.98 | |
| Low | 216.08 | |
| Volume | 914,377 | |
| Change | -2.55 | |
| Change % | -1.15 | |
| Avg Volume (20 Days) | 1,364,648 | |
| Volume/Avg Volume (20 Days) Ratio | 0.67 | |
| 52 Week Range | 189.44 - 319.76 | |
| Price vs 52 Week High | -31.55% | |
| Price vs 52 Week Low | 15.54% | |
| Range | -1.19 | |
| Gap Up/Down | -0.88 | |
Fundamentals | ||
| Market Capitalization (Mln) | 33,570 | |
| EBIDTA | 2,519,800,064 | |
| PE Ratio | 27.6875 | |
| PEG Ratio | 6.2424 | |
| WallStreet Target Price | 283.79 | |
| Book Value | 104.4850 | |
| Earnings Per Share | 8.0000 | |
| EPS Estimate Current Quarter | 3.4500 | |
| EPS Estimate Next Quarter | 3.9400 | |
| EPS Estimate Current Year | 15.6000 | |
| EPS Estimate Next Year | 17.4000 | |
| Diluted EPS (TTM) | 8.0000 | |
| Revenues | ||
| Profit Marging | 0.1207 | |
| Operating Marging (TTM) | 0.2728 | |
| Return on asset (TTM) | 0.0486 | |
| Return on equity (TTM) | 0.0805 | |
| Revenue TTM | 9,663,099,904 | |
| Revenue per share TTM | 66.6880 | |
| Quarterly Revenue Growth (YOY) | -0.0700 | |
| Quarterly Earnings Growth (YOY) | 0.0110 | |
| Gross Profit (TTM) | 7,895,100,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 27.6875 | |
| Forward PE | 13.0039 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.9465 | |
| Revenue Enterprise Value | 3.5683 | |
| EBITDA Enterprise Value | 17.2165 | |
| Shares | ||
| Shares Outstanding | 145,596,992 | |
| Shares Float | 145,052,363 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 0.16 | |
| Institutions (%) | 94.37 | |
05/16 14:07 EST - marketwatch.com
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
The stocks of Biogen Inc. and Ionis Pharmaceuticals Inc. were lower Thursday, after the partners said they were terminating development of a treatment for the fatal disease Amyotrophic Lateral Sclerosis, or ALS, after a disappointing trial.
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
The stocks of Biogen Inc. and Ionis Pharmaceuticals Inc. were lower Thursday, after the partners said they were terminating development of a treatment for the fatal disease Amyotrophic Lateral Sclerosis, or ALS, after a disappointing trial.
05/16 07:41 EST - reuters.com
Biogen, Ionis to discontinue development of ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study.
Biogen, Ionis to discontinue development of ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study.
05/16 07:30 EST - prnewswire.com
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CARLSBAD, Calif. and CAMBRIDGE, Mass.
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CARLSBAD, Calif. and CAMBRIDGE, Mass.
05/16 07:30 EST - globenewswire.com
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
CAMBRIDGE, Mass. and CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on topline results from the Phase 1/2 ALSpire study. BIIB105 was designed to reduce expression of ataxin-2 (ATXN2) protein and demonstrated statistically significant cerebrospinal fluid (CSF) ATXN2 protein reductions in the study. However, over the 6-month placebo-controlled period, treatment with BIIB105 did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage. Additionally, BIIB105 did not demonstrate an impact on clinical outcome measures of function, breathing, and strength.
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
CAMBRIDGE, Mass. and CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on topline results from the Phase 1/2 ALSpire study. BIIB105 was designed to reduce expression of ataxin-2 (ATXN2) protein and demonstrated statistically significant cerebrospinal fluid (CSF) ATXN2 protein reductions in the study. However, over the 6-month placebo-controlled period, treatment with BIIB105 did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage. Additionally, BIIB105 did not demonstrate an impact on clinical outcome measures of function, breathing, and strength.
05/15 13:15 EST - zacks.com
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
05/14 19:33 EST - globenewswire.com
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).
05/11 08:00 EST - investorplace.com
3 S&P 500 Stocks to Rival Nvidia's 2023 Performance in the Second Half of 2024
The extraordinary performance of Nvidia (NASDAQ: NVDA ) in 2023 coincided with a seismic generative-AI rally that carried the entirety of the S&P 500 higher in a year that was punctuated by Fed interest rate hikes and geopolitical uncertainty. Now, with the expectations of rate cuts finally arriving in the second half of 2024, we can look to more stocks posting similar levels of impressive growth backed by a more positive market outlook.
3 S&P 500 Stocks to Rival Nvidia's 2023 Performance in the Second Half of 2024
The extraordinary performance of Nvidia (NASDAQ: NVDA ) in 2023 coincided with a seismic generative-AI rally that carried the entirety of the S&P 500 higher in a year that was punctuated by Fed interest rate hikes and geopolitical uncertainty. Now, with the expectations of rate cuts finally arriving in the second half of 2024, we can look to more stocks posting similar levels of impressive growth backed by a more positive market outlook.
05/09 06:30 EST - investorplace.com
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Here's a question for you: What determines the value of a drug? Is it the number of lives it saves or how much it costs to make?
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Here's a question for you: What determines the value of a drug? Is it the number of lives it saves or how much it costs to make?
05/02 07:30 EST - globenewswire.com
Biogen Reports Progress on Corporate Responsibility Priorities
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company's commitment to making responsible business decisions in the best interests of all its stakeholders.
Biogen Reports Progress on Corporate Responsibility Priorities
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company's commitment to making responsible business decisions in the best interests of all its stakeholders.
04/29 10:03 EST - investorplace.com
7 Retirement Stocks to Buy at a 52-Week Low in April
One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It's even better if you're buying into a reputable company that's paid out dividends for years, and is on sale.
7 Retirement Stocks to Buy at a 52-Week Low in April
One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It's even better if you're buying into a reputable company that's paid out dividends for years, and is on sale.
04/25 16:05 EST - globenewswire.com
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been recommended for approval for the treatment of moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been recommended for approval for the treatment of moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.
04/24 18:18 EST - fool.com
Why Biogen Stock Leaped Nearly 5% Higher Today
The biotech handily beat the average analyst estimate for profitability. Investors were surely happy about this, but they might have been more impressed by the sales of a promising drug that recently won approval.
Why Biogen Stock Leaped Nearly 5% Higher Today
The biotech handily beat the average analyst estimate for profitability. Investors were surely happy about this, but they might have been more impressed by the sales of a promising drug that recently won approval.
04/24 17:05 EST - youtube.com
3-Stock Lunch: TXN, BIIB & CMG
Jerry Castellini, Castle Ark co-founder, joins ‘Power Lunch' to discuss plays for three stocks including: Texas Instruments, Biogen and Chipotle Mexican.
3-Stock Lunch: TXN, BIIB & CMG
Jerry Castellini, Castle Ark co-founder, joins ‘Power Lunch' to discuss plays for three stocks including: Texas Instruments, Biogen and Chipotle Mexican.
04/24 14:01 EST - zacks.com
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
04/24 11:25 EST - seekingalpha.com
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q1 2024 Earnings Call Transcript April 24, 2024 5:00 PM ET Company Participants Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Officer Alisha Alaimo - Head and President of North-America Mike McDonnell - Chief Financial Officer Priya Singhal - Head of Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald Paul Matteis - Stifel Salveen Richter - Goldman Sachs Umer Raffat - Evercore ISI Michael Yee - Jefferies Colin Bristow - UBS Brian Abrahams - RBC Capital Markets Jay Olson - Oppenheimer Chris Raymond - Piper Sandler Terence Flynn - Morgan Stanley Operator Good morning. My name is Jennifer, and I will be your conference operator today.
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q1 2024 Earnings Call Transcript April 24, 2024 5:00 PM ET Company Participants Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Officer Alisha Alaimo - Head and President of North-America Mike McDonnell - Chief Financial Officer Priya Singhal - Head of Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald Paul Matteis - Stifel Salveen Richter - Goldman Sachs Umer Raffat - Evercore ISI Michael Yee - Jefferies Colin Bristow - UBS Brian Abrahams - RBC Capital Markets Jay Olson - Oppenheimer Chris Raymond - Piper Sandler Terence Flynn - Morgan Stanley Operator Good morning. My name is Jennifer, and I will be your conference operator today.
04/24 10:36 EST - zacks.com
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
04/24 08:51 EST - barrons.com
Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales
Biogen says first-quarter global in-market sales of Leqembi were about $19 million, nearly triple the fourth quarter of 2023.
Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales
Biogen says first-quarter global in-market sales of Leqembi were about $19 million, nearly triple the fourth quarter of 2023.
04/24 07:45 EST - invezz.com
Biogen Q1 2024 results surpass expectation despite revenue decline
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quarter of 2024, Biogen reported a revenue of $2.29 billion, which slightly missed expectations by $30 million.
Biogen Q1 2024 results surpass expectation despite revenue decline
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quarter of 2024, Biogen reported a revenue of $2.29 billion, which slightly missed expectations by $30 million.